◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

首页全部股票 › 4553 · English version

Towa Pharmaceutical Co., Ltd. (4553)

来自官方财务报表的收入、利润与现金流历史。

Healthcare · 华尔街(美国) · 最近更新: 2026-08-11

东和制药株式会社及其子公司在日本生产和销售符合伦理道德的药品。该公司通过两个部门运营;国内和海外。它提供消化系统、神经系统和过敏性疾病治疗领域的产品,以及维生素、抗生素和肿瘤产品,并提供片剂、胶囊、注射剂、贴剂、滴眼剂和其他产品的配方。该公司还提供与医疗保健相关的IT服务;疾病风险检测服务;以及医药部外品的销售。此外,还涉足医药原料药、中间体及配套业务的研发和生产;保健食品、医药品、普通食品及其他杂货的策划、开发及OEM制造。东和制药株式会社成立于1951年,总部位于日本门真市。

机器翻译

关键数据

查看交互式图表与完整报表 →

年度利润表

利润表2026-03-312025-03-312024-03-312023-03-31
总收入JPY 273.7BJPY 259.6BJPY 227.9BJPY 208.9B
毛利JPY 99.1BJPY 94.7BJPY 81.4BJPY 72.7B
营业利润(EBIT)JPY 23.1BJPY 23.2BJPY 17.6BJPY 5.5B
净利JPY 5.2BJPY 19.0BJPY 16.2BJPY 2.2B

来源:公司公开报告(SEC)。在依赖任何数字前请核对 SEC EDGAR。

资产负债表、现金流、季度数据与完整财务比率见 4553 交互式查看器。 /companies/us/4553

类似公司

本网站信息仅用于教育与参考,不构成投资建议。不发布目标价或买卖建议。

English version →全部股票

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.